首页> 外文期刊>Neuroscience Letters: An International Multidisciplinary Journal Devoted to the Rapid Publication of Basic Research in the Brain Sciences >Differential effects of remacemide and desglycinyl-remacemide on epileptiform burst firing in the rat hippocampal slice.
【24h】

Differential effects of remacemide and desglycinyl-remacemide on epileptiform burst firing in the rat hippocampal slice.

机译:瑞卡美胺和去糖基-瑞卡美胺对大鼠海马切片癫痫样放电放电的差异作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Remacemide is a potential anticonvulsant drug with an active metabolite, desglycinyl-remacemide (DGR). Both moieties have been reported to block neuronal Na(+) channels and the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. The effects of remacemide and DGR on zero Mg(2+)/4-aminopyridine-induced epileptiform discharges were investigated in the rat hippocampal slice preparation and compared with carbamazepine (CBZ), a prototypic Na(+) channel blocker, and AR-R15896AR, a putative NMDA channel blocker. Remacemide (0-100 microM) was without significant effect, while DGR, CBZ and AR-R15896AR all decreased burst frequency in a concentration (0-100 microM) dependent manner. These findings suggest that remacemide is not sufficiently potent at the Na(+) channel or NMDA receptor to attenuate epileptiform activity in this model and that the anticonvulsant effects of the drug may be mediated by DGR.
机译:Remacemide是一种潜在的抗惊厥药,具有活性代谢物desglycinyl-remacemide(DGR)。据报道这两个部分都阻止神经元Na(+)通道和谷氨酸受体的N-甲基-D-天冬氨酸(NMDA)亚型。在大鼠海马切片制备中研究了瑞格美胺和DGR对Mg(2 +)/ 4-氨基吡啶诱导的癫痫样放电为零的影响,并与卡马西平(CBZ),原型Na(+)通道阻滞剂和AR-R15896AR ,一种推定的NMDA通道阻止程序。雷米卡米(0-100 microM)没有显着影响,而DGR,CBZ和AR-R15896AR均以浓度依赖性(0-100 microM)降低了猝发频率。这些发现表明,在该模型中,瑞马克美在Na(+)通道或NMDA受体上的效力不足以减弱癫痫样活动,并且该药物的抗惊厥作用可能由DGR介导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号